209 related articles for article (PubMed ID: 32846794)
21. Mortality of Chinese patients with polymyositis and dermatomyositis.
Yang X; Hao Y; Zhang X; Geng Y; Ji L; Li G; Zhang Z
Clin Rheumatol; 2020 May; 39(5):1569-1579. PubMed ID: 31902027
[TBL] [Abstract][Full Text] [Related]
22. Risk of Malignancy in Dermatomyositis and Polymyositis.
Qiang JK; Kim WB; Baibergenova A; Alhusayen R
J Cutan Med Surg; 2017; 21(2):131-136. PubMed ID: 27534779
[TBL] [Abstract][Full Text] [Related]
23. [Predictive factors and unfavorable prognostic factorial analysis of interstitial lung disease in patients with inflammatory myopathy].
Li R; Li XP; Li XM; Wang GS; Qian L; Tao JH; Ma Y; Zhang H
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(33):2335-8. PubMed ID: 23158563
[TBL] [Abstract][Full Text] [Related]
24. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.
Azuma K; Yamada H; Ohkubo M; Yamasaki Y; Yamasaki M; Mizushima M; Ozaki S
Mod Rheumatol; 2011 Apr; 21(2):178-83. PubMed ID: 20922453
[TBL] [Abstract][Full Text] [Related]
25. Cancer risk in dermatomyositis: a systematic review of the literature.
Di Rollo D; Abeni D; Tracanna M; Capo A; Amerio P
G Ital Dermatol Venereol; 2014 Oct; 149(5):525-37. PubMed ID: 24975953
[TBL] [Abstract][Full Text] [Related]
26. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis.
Hoesly PM; Sluzevich JC; Jambusaria-Pahlajani A; Lesser ER; Heckman MG; Abril A
J Am Acad Dermatol; 2019 May; 80(5):1364-1370. PubMed ID: 30458207
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.
Liu Y; Xu L; Wu H; Zhao N; Tang Y; Li X; Liang Y
Oncol Lett; 2018 Nov; 16(5):5960-5968. PubMed ID: 30344746
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis.
Fardet L; Dupuy A; Gain M; Kettaneh A; Chérin P; Bachelez H; Dubertret L; Lebbe C; Morel P; Rybojad M
Medicine (Baltimore); 2009 Mar; 88(2):91-97. PubMed ID: 19282699
[TBL] [Abstract][Full Text] [Related]
29. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
30. Complex repetitive discharge on electromyography as a risk factor for malignancy in idiopathic inflammatory myopathy.
Kim NR; Nam EJ; Kang JW; Song HS; Im CH; Kang YM
Korean J Intern Med; 2014 Nov; 29(6):814-21. PubMed ID: 25378981
[TBL] [Abstract][Full Text] [Related]
31. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
32. Dermatomyositis and malignancy: a retrospective study of 115 cases.
Zhang W; Jiang SP; Huang L
Eur Rev Med Pharmacol Sci; 2009; 13(2):77-80. PubMed ID: 19499841
[TBL] [Abstract][Full Text] [Related]
33. Incidence of malignancies in biopsy-proven inflammatory myopathy.
Kannan MA; Sundaram C; Uppin M; Mridula R; Jabeen SA; Borgohain R
Neurol India; 2013; 61(2):152-5. PubMed ID: 23644314
[TBL] [Abstract][Full Text] [Related]
34. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for cancer-associated myositis: A large-scale multicenter cohort study.
Li Y; Jia X; Sun X; Shi L; Lin F; Gan Y; Zhang X; Gao X; Miao M; Hong D; Li Y; He J
Int J Rheum Dis; 2021 Feb; 24(2):268-273. PubMed ID: 33369084
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center.
Chen F; Zuo Y; Li S; Shi J; Wang G; Shu X
Respir Med; 2019 Aug; 155():127-132. PubMed ID: 31344662
[TBL] [Abstract][Full Text] [Related]
37. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Xing X; Li A; Li C
Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
[TBL] [Abstract][Full Text] [Related]
38. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.
Sparsa A; Liozon E; Herrmann F; Ly K; Lebrun V; Soria P; Loustaud-Ratti V; Bouyssou-Gauthier ML; Boulinguez S; Bédane C; Jauberteau MO; Vidal E; Bonnetblanc JM
Arch Dermatol; 2002 Jul; 138(7):885-90. PubMed ID: 12071815
[TBL] [Abstract][Full Text] [Related]
39. A retrospective cohort study in Chinese patients with adult polymyositis and dermatomyositis: risk of comorbidities and subclassification using machine learning.
Zhu J; Wu L; Zhou Y; Wang R; Chen S; Zhao J; Yu S; Zheng S; Xiao F; Ren H; Yang M; Li J
Clin Exp Rheumatol; 2022 Feb; 40(2):224-236. PubMed ID: 34251311
[TBL] [Abstract][Full Text] [Related]
40. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.
Wang Q; Gao C; Zhang C; Yao M; Liang W; Sun W; Zheng Z
Clin Rheumatol; 2022 Jun; 41(6):1731-1739. PubMed ID: 35138465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
